Quality of life among older adults with HIV after switching to bictegravir‐based three‐drug or dolutegravir‐based two‐drug regimens
HIV Medicine · 2026-11 · 27 (11) · 1896-1902
DOI: 10.1111/hiv.70310 ↗Abstract
Abstract Background Data on adults aged ≥60 years with HIV remain limited, despite their increasing representation in clinical practice. We evaluated whether age ≥60 years was associated with reasons for treatment switch, quality of life (QoL) and clinical outcomes among adults with HIV switching antiretroviral therapy in routine care. Methods We performed a cross‐sectional analysis of prospectively collected data from a real‐world cohort established in 2018, including adults with HIV aged ≥50 years who switched to bictegravir‐based three‐drug regimens (BIC 3DR) or dolutegravir‐based two‐drug regimens (DTG 2DR). Participants were stratified by age (≥60 vs.
EUVIMED